Latest News


June 2021

iX Biopharma Ltd is set to expand its current wafer production capacity at its manufacturing facility in Australia, following the installation and commissioning of its new freeze-dry production equipment...

Read On


May 2021

iX Biopharma is pleased to announce that the US FDA has granted the Company an orphan drug designation for treatment of patients with Complex Regional Pain Syndrome (CRPS) with ketamine...

Read On

Our Sublingual Technology

Sublingual wafer administration offers the convenience of use over oral delivery, circumventing the drug breakdown in liver or gastrointestinal tract. The technology also provides rapid absorption, achieving maximum desirable therapeutic effect in a non-invasive manner.

Read On

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170